Vascular Closure Devices Market

Future Market Insights suggests that within the vascular closure devices landscape, Haemonetics' USD 116 million acquisition of Vivasure Medical for large-bore structural heart closure, Teleflex's definitive agreement to acquire Biotronik's Vascular Intervention business, and Cordis's FDA approval and Premier national agreement for the MYNX CONTROL Venous device are creating a structural expansion from traditional femoral arterial closure into venous, large-bore, and structural heart access site management. Analysts identify the large-bore venous closure modality (Haemonetics VASCADE MVP XL, Vivasure) and the PEG-sealant venous closure technology (Cordis MYNX CONTROL Venous) as the central pivot points for the industry, effectively expanding the addressable market from standard 5-8 French arterial access to 10-15+ French multi-access venous closure in electrophysiology and structural heart procedures.